We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Levosimendan vs Dobutamine for Patients With Acute Decompensated Heart Failure.
- Authors
Mebazaa, Alexandre; Nieminen, Markku S.; Packer, Milton; Cohen-Solal, Alain; Kleber, Franz X.; Pocock, Stuart J.; Thakkar, Roopal; Padley, Robert J.; Põder, Pentti; Kivikko, Matti
- Abstract
This article presents the results of the clinical trial "Levosimendan vs Dobutamine for Patients with Acute Decompensated Heart Failure: The SURVIVE Randomized Trial." Background on the study was the desire for further knowledge of how to best treat patients with Acute Decompensated Heart Failure (ADHF). ADHF causes substantial morbidity and mortality and there is a need for agents that improve hemodynamics without adversely affecting survival. The study assessed the effect of a short-term intravenous drip of levosimendan or dobutamine on long-term survival. The setting, design and patients are reported on. The results are given and the conclusion was that patients in the levosimenden group compared with those in the dobutamine group. Levosimenden did not significantly reduce all-cause mortality at 180 days for affect any secondary clinical outcomes.
- Subjects
HEART failure treatment; HEMODYNAMICS; CARDIAC volume; BLOOD circulation; DRUG efficacy; DOBUTAMINE; MORTALITY; DISEASES; CLINICAL trials; THERAPEUTICS
- Publication
JAMA: Journal of the American Medical Association, 2007, Vol 297, Issue 17, p1883
- ISSN
0098-7484
- Publication type
Article
- DOI
10.1001/jama.297.17.1883